Influence of HIV and other risk factors on tuberculosis by Mahtab, Sana & Coetzee, David
428       May 2017, Vol. 107, No. 5
RESEARCH
The HIV epidemic in Africa has not only dramatically increased the 
incidence of tuberculosis (TB) in this region, but has also increased 
the TB mortality rate. Co-infected patients are also more likely to die 
from TB, which is more easily curable in HIV-negative patients.[1] The 
rate of unfavourable treatment outcome for HIV-positive pulmonary 
TB patients in some African countries is now as high as 20% for 
sputum smear-positive cases and 50% for sputum smear-negative 
cases.[2,3] Deaths from TB represent a significant indicator of the 
severity of the effect of HIV on TB epidemiology.[1] Extrapulmonary 
TB (EPTB), which is also a risk factor for unfavourable outcome, is 
20 - 70% more common in HIV-positive patients.[4]
In 2013, there were 1.5 million deaths from TB globally, 360 000 
of them associated with HIV.[5] Globally TB is the most common 
opportunistic infection in HIV-positive patients. Wood et al.[6] 
reported a 17 times higher risk of developing TB disease in HIV-
positive populations than in HIV-negative populations. TB has a 
negative impact on HIV, increasing the risk of HIV-related morbidity 
and mortality[7] through the increased replication of HIV cell lines 
and activation of mononuclear cells, increasing the progression of 
HIV infection and susceptibility to other infections, and decreasing 
the time to development of AIDS.[8]
The increased mortality rate of TB patients in high HIV prevalence 
populations in Africa may change the general perception of TB as 
a curable disease and threaten the reputation of TB programmes. 
This may have an adverse influence on the willingness of individuals 
suspected of having TB to come forward for diagnosis and complete 
TB treatment.[1]
According to South African (SA) data, TB was the leading cause 
of death in persons 15 - 24 years of age in 2010, accounting for 14% 
of all deaths.[9] In 2013, the World Health Organization (WHO) 
reported that 62% of TB patients in SA were co-infected with HIV.[10] 
Co-infected patients have poorer treatment outcomes than patients 
who are HIV-negative. In 2011, the treatment success rate globally 
was 73% in co-infected patients and 87% in HIV-negative patients. [11] 
In 2013, the incidence of TB in persons co-infected with HIV was 
520 per 100 000 in SA and mortality was 121 per 100 000, more than 
double the rate of 48 per 100 000 in HIV-negative persons.[10]
Objectives
The primary objective of this study was to describe the 
sociodemographic and outcome characteristics of TB patients in the 
Metro East geographical service area (GSA), Cape Town, SA. The 
secondary objective was to identify risk factors associated with TB 
treatment outcomes stratified by HIV status.
Methods
Study design
A cross-sectional study was conducted using quantitative research 
methods on data from the electronic TB register (ETR.Net). ETR.
Net is an electronic TB register that monitors all patients treated 
for drug-sensitive TB at public sector health facilities. The register 
is prospectively completed as the person progresses though their 
course of TB treatment. It contains the following information: date 
of treatment initiation, basic demographics, previous TB treatment, 
laboratory test results at initiation, at 2 or 3 months and at completion 
of treatment, and HIV status. In most facilities, this information is 
collected in a paper TB register and then transferred to ETR.Net 
at subdistrict level. This information is used to generate standard 
reports and provide data on the quality of services, so that the TB 
strategy and programme can be monitored and evaluated.
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Study setting
The district of Cape Town is divided into two GSAs, Metro East 
and Metro West. Data for the Metro East GSA were analysed in this 
project. The Metro East GSA consists of the Eastern, Khayelitsha, 
Northern and Tygerberg subdistricts.
Population
The study population included persons aged ≥15 years, placed on TB 
treatment regimens 1 or 2 at public sector TB services in the Metro 
East GSA of Cape Town and registered on ETR.Net for TB treatment 
initiation from 1 July 2011 to 30 June 2012. The study only included 
individuals whose HIV status was known.
Ethics approval
Ethics approval was obtained from the Human Research Ethics 
Committee of the Faculty of Health Sciences at the University of 
Cape Town (UCT) (ref. no. 758/2014). The names and addresses of 
all participants were removed from the database before the study was 
conducted.
TB treatment outcome
The WHO classifies TB treatment outcomes into one of six cate-
gories: completed, cured, failed, died, defaulted and outcome un- 
known.[5]
Definitions:
• Cure. Patient smear- or culture-positive at the beginning of treat-
ment and smear/culture-negative in the last month of treatment 
and on at least one previous occasion at least 30 days before that.[5]
• Treatment completed. Patient smear/culture-positive at the begin-
ning and has completed treatment but did not have a negative 
smear/culture in the last month of treatment and on at least one 
previous occasion >30 days before that. The smear examination may 
not have been done or the results may not be available at the end of 
treatment.[5]
• Treatment success. Includes both treatment completion and cure.[5]
• Treatment default. Patient whose treatment was interrupted for 
2 consecutive months or more during the treatment period.[5]
• Treatment failure. Smear/culture-positive patient who remains 
or is again smear-positive at 5 months or later during treatment. 
This definition also includes patients who are diagnosed with 
multidrug-resistant TB during treatment.[5]
• Treatment unsuccessful. Includes both treatment default and 
treat ment failure.
• Died. Death for any reason during TB treatment.[5]
• Unfavourable treatment outcome. Includes treatment default, 
treatment failure and death.
Data analysis
All selected data were exported from Microsoft Excel version 
2010 (Microsoft, USA) into STATA version 12.1 (StataCorp, USA) 
for analysis. Univariate analysis explored the distribution of the 
dependent and independent variables using frequency tables.
Bivariate analysis identified risk factors that were associated with 
HIV status and other risk factors and TB treatment outcomes. For the 
bivariate analysis, treatment default, treatment failure and death were 
merged into one variable, namely unfavourable treatment outcome. 
Pearson’s χ2 statistic was used to compare categorical variables, and 
p<0.05 was considered statistically significant.
Relative risks (RRs) were used for measures of association. 
Univariate and multivari ate analyses were performed using a 
generalised linear regression model. Statistically significant variables 
in the univariate analysis were included in the multivariate analysis. 
The contribution of each variable to the model was evalu ated using 
likelihood ratio χ2 tests.
Results
Between 1 July 2011 and 30 June 2012, 14 585 patients aged 
≥15  years were initiated on TB treatment and registered on the 
TB ETR.Net in the Metro East GSA. The study sample comprised 
12 672 patients after 1 913 were excluded because they were not on 
treatment regimen 1 or 2, their HIV status was not known, or they 
had been transferred into or out of the district (Fig. 1).
Table 1 presents the demographic characteristics, treatment 
category, site of TB, subdistrict where treated and diagnostic sputum 
smear microscopy results. Of patients initiated on TB treatment from 
1 July 2011 to 30 June 2012, 77.4% were between 15 and 44  years 
of age. The majority were males (54.5%). The subdistrict with the 
highest proportion of the TB cases in the GSA was Khayelitsha 
(37.0%) and the lowest was Northern (14.9%). Of TB patients, 50.5% 
were co-infected with HIV. Retreatment cases accounted for 30.4% of 
all cases, 83.4% of cases were classified as pulmonary TB, 88.8% of the 
patients had a diagnostic sputum smear microscopy result, and 46.5% 
of the patients had a positive sputum smear result.
Of HIV co-infected patients, 56.1% were aged 30 - 44 years, 53.3% 
were female, 47.6% were from Khayelitsha, 28.1% had an unsuccessful 
treatment outcome and 5.3% died (Table 2). More HIV co-infected 
than HIV-negative patients were under retreatment (33.2% v. 27.6%, 
respectively), and more had EPTB and both pulmonary TB and EPTB 
(18.6% v. 9.8% and 3.5% v. 1.4%, respectively).
Of all TB patients in the GSA, 70.0% had a successful treatment 
outcome, 25.9% had unsuccessful treatment and 4.1% died; 66.1% of 
patients who died and 54.7% of those who had unsuccessful treatment 
were co-infected, whereas 48.0% of those with a successful treatment 
success outcome were co-infected. Khayelitsha was the district with 
the highest proportion of unsuccessful outcomes (43.4%) and deaths 
(38.7%) (Table 3).
TB case notification among districts
Based on the population census of 2011,[12] the TB case notification 
rate calculated for the Metro East GSA was 922 per 100 000. Rates 
of TB case notification and proportions of TB patients with HIV 
co-infection for each subdistrict are presented in Table 4, which also 
includes the annual HIV seroprevalence rates from the 2012 antenatal 
survey.[13] The trend for HIV co-infection across subdistricts matches 
the seroprevalence of HIV in the antenatal survey.
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Fig. 1. Selection of the population included in the study.
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Sputum smear conversion rates at the end of the 
intensive phase and at the end of treatment, stratified  
by HIV status
In total, 11 255 patients had a diagnostic sputum smear sent to the 
laboratory for microscopy and 5 889 (52.3%) of these were positive; 
of patients with a positive sputum smear, 2 063 (35.0%) were HIV-
positive and 3 826 (65.0%) were HIV-negative.
Fig. 2 (A) shows that at the end of the intensive phase, 1 707 
(82.7%) of HIV-positive patients who had a positive sputum smear 
at initiation had a negative smear, 88 (4.3%) remained positive and 
311 (15.1%) did not have a smear. At the end of treatment, 14 smears 
(0.7%) remained positive, but 703 patients (34.1%) did not have a 
smear. In terms of outcome, 102 (14.5%) of the 703 patients who did 
not have a smear died, 55 (7.8%) had a successful outcome and 546 
(77.7%) had an unsuccessful outcome.
Fig. 2 (B) shows that at the end of the intensive phase, 3 331 
(87.1%) of HIV-negative patients who had a positive sputum smear 
at initiation had a negative smear, 265 (6.9%) remained positive and 
375 (9.8%) did not have a smear. At the end of treatment, 25 smears 
(0.7%) remained positive but 1 003 (26.2%) did not have a smear. In 
terms of outcome, 66 (6.6%) of the 1 003 patients who did not have a 
smear died, 84 (8.4%) had a successful outcome and 853 (85.1%) had 
an unsuccessful outcome.
Sputum smear microscopy and culture results  
at diagnosis
Of 6 397 HIV-positive patients, 5 466 (85.4%) had a smear test, and 
of these only 3 559 (65.1%) had smear culture. Of 6 275 HIV-negative 
patients, 5 789 (92.2%) had a smear test and of these only 2 827 
(48.8%) had smear culture. Table 5 shows that the sensitivity of the 
sputum smear in HIV-positive patients was low (47.1%) compared 
with that in HIV-negative patients (68.1%). The specificity of the 
sputum smear was 9% higher in HIV-positive patients than in HIV-
negative patients.
Risk factors for an unfavourable treatment outcome
In the multivariate analysis, HIV co-infection (RR 1.2), retreatment 
(RR 1.4) and smear not done (RR 1.4) were significant risk factors for 
an unfavourable treatment outcome (Table 6).
Patients in the Eastern (RR 0.9) and Northern (RR 0.7) subdistricts 
were less likely to have had an unfavourable treatment outcome than 
those in the Khayelitsha subdistrict.
When stratified by HIV status, retreatment and smear not done 
were significantly associated with unfavourable treatment outcomes 
in HIV-negative TB patients, while being from the Northern and 
Eastern subdistricts compared with Khayelitsha was associated with 
a favourable outcome.
Co-infected patients aged <59 years compared with those aged 
15 - 29 years, and co-infected patients who had a negative diagnostic 
smear recorded compared with those who had a positive smear, 
were less likely to have an unfavourable outcome. Patients who 
Table 1. Demographic characteristics, HIV status, treatment 
category, site of TB, diagnostic sputum smear microscopy 
results and treatment outcome of patients (N=12 672) initia-
ted on TB treatment in the Metro East GSA, Cape Town
Variables n (%)
Age (years)
15 - 29 4 360 (34.4)
30 - 44 5 443 (43.0)
45 - 59 2 372 (18.7)
>59 497 (3.9)
Sex
Female 5 766 (45.5)
Male 6 906 (54.5)
Subdistrict 
Khayelitsha 4 683 (37.0)
Eastern 2 941 (23.2)
Northern 1 892 (14.9)
Tygerberg 3 156 (24.9)
HIV status
Negative 6 275 (49.5)
Positive 6 397 (50.5)
Category 
New 8 816 (79.6)
Retreatment 3 856 (30.4)
Disease classification 
Pulmonary 10 564 (83.4)
Extrapulmonary 1 802 (14.2)
Both 306 (2.4)
Sputum smear diagnostic result
Positive 5 889 (46.5)
Negative 5 366 (42.3)
No smear 1 417 (11.2)
Treatment outcome
Treatment successful 8 870 (70.0)
Treatment unsuccessful 3 288 (25.9)
Died 514 (4.1)
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Fig. 2. Diagnostic sputum smear result and conversion at the end of the 
intensive phase and at the end of treatment in HIV-positive patients (A) and 
HIV-negative patients (B).
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had previously had TB (retreatment cases) were significantly more 
likely than new patients to have an unfavourable treatment outcome 
(RRs 1.6 for HIV-negative and 1.3 for co-infected patients).
HIV-negative TB patients from the Eastern and Northern sub-
districts were more likely to have a favourable outcome than those 
from Khayelitsha, while retreatment compared with new patients 
and those who did not have a smear compared with those who had 
a positive smear were more likely to have an unfavourable outcome.
Discussion
Our study showed that the incidence of TB in the Metro East GSA 
was high at 922 per 100 000. This is alarming. According to the 
2014 WHO TB report, the incidence of TB was 125 per 100 000 
population globally, 165 per 100 0000 in 22 high-burden countries 
and 860 per 100 000 in South Africa.[5] The incidence in the Western 
Cape Province of SA was 885 per 100 000 population,[14] and in Cape 
Town it was 877 per 100 000 population in 2009 and 663 per 100 000 
population in 2013.[15] One of the main reasons for the high incidence 
is the high prevalence of HIV in some of these areas.[16]
In the Metro East GSA of Cape Town, 96.7% of TB patients had 
been tested for HIV. This shows that the recommendation that all 
TB patients be screened for HIV has been successfully implemented. 
Half of the TB patients in this study were co-infected with HIV. This 
high co-infection rate was due to the inclusion of the Khayelitsha 
subdistrict, which has the highest co-infection rate in the Western 
Cape.[16] Khayelitsha, with the highest antenatal HIV prevalence, had 
both the highest rate of TB and the highest co-infection rate, while 
Tygerberg had a comparatively high TB incidence but the lowest 
prevalence of co-infection.[16] HIV is therefore not the sole reason 
for the TB epidemic. Other developing countries such as Pakistan, 
India and China have a low prevalence of HIV but a high incidence 
of TB.[17-19]
In this study, 45.5% of TB patients were female, but more 
females than males were HIV co-infected (of HIV-positive patients 
53.3% were female, compared with 37.5% of HIV-negative patients). 
Co-infected females were also younger than their male counterparts. 
The epidemic of TB in terms of sex has changed as a result of the 
HIV epidemic. Before the era of HIV the male-to-female ratio for TB 
incidence was 2:1,[20] but the high prevalence of HIV in females has 
led to an increased incidence of TB among females.[21] A number of 
studies and reports have shown that women of childbearing age were 
more likely than the older women to develop TB due to co-infection 
with HIV.[22,23]
In this study, 14.2% of patients with TB had EPTB, and 65.9% of 
them were co-infected with HIV. This is similar to other studies that 
showed that EPTB was more common in co-infected patients.[24,25]
Table 2. Demographic characteristics, HIV status, treatment 
category, site of TB, subdistrict where treated and diagnostic 
sputum smear microscopy results of patients initiated on TB 
treatment in the Metro East GSA, Cape Town, stratified by 
HIV status
Variables
HIV-negative 
(N=6 275), n (%)
HIV-positive 
(N=6 397), n (%)
Age (years)
15 - 29 2 606 (41.5) 1 754 (27.4)
30 - 44 1 855 (29.6) 3 588 (56.1)
45 - 59 1 405 (22.4) 967 (15.1)
>59 409 (6.5) 88 (1.4)
Sex
Female 2 356 (37.5) 3 410 (53.3)
Male 3 919 (62.5) 2 987 (46.7)
Subdistrict
Khayelitsha 1 640 (26.1) 3 043 (47.6)
Eastern 1 594 (25.4) 1 347 (21.0)
Northern 875 (13.9) 1 017 (15.9)
Tygerberg 2 166 (34.5) 990 (15.5)
Outcome
Treatment successful 4 612 (73.5) 4 258 (66.6)
Treatment unsuccessful 1 489 (23.7) 1 799 (28.1)
Died 174 (2.8) 340 (5.3)
Category 
New 4 541 (72.3) 4 275 (66.8)
Retreatment 1 734 (27.6) 2 122 (33.2)
Disease classification
Pulmonary 5 575 (88.8) 4 989 (78.0)
Extrapulmonary 615 (9.8) 1 187 (18.6)
Both 85 (1.4) 221 (3.5)
Smear diagnostic result
Positive 3 826 (61.0) 2 063 (32.2)
Negative 1 963 (31.3) 3 403 (53.2)
No smear 486 (7.7) 931 (14.6)
Table 3. Demographic characteristics, HIV status, treatment 
category, site of TB and diagnostic sputum smear microscopy 
results of patients initiated on TB treatment in the Metro 
East GSA, Cape Town, stratified by treatment outcome
Variables
Treatment 
successful 
(N=8 870), 
n (%)
Treatment 
unsuccessful 
(N=3 288), 
n (%)
Died 
(N=514),  
n (%) 
Age (years)
15 - 29 3 106 (35.0) 1 176 (35.8) 78 (15.2)
30 - 44 3 754 (42.3) 1 469 (44.7) 220 (42.8)
45 - 59 1 689 (19.0) 530 (16.1) 153 (39.8)
>59 321 (3.6) 113 (3.4) 63 (12.3)
Sex
Female 4 068 (46.8) 1 477 (44.9) 221 (43.0)
Male 4 802 (54.1) 1 811 (55.1) 293 (57.0)
Subdistrict
Khayelitsha 3 056 (34.5) 1 428 (43.4) 199 (38.7)
Eastern 2 128 (24.0) 722 (22.0) 91 (17.7)
Northern 1 462 (16.5) 357 (10.9) 73 (14.2)
Tygerberg 2 224 (25.1) 781 (24.0) 151 (29.4)
HIV status
Negative 4 612 (52.0) 1 489 (45.3) 174 (33.9)
Positive 4 258 (48.0) 1 799 (54.7) 340 (66.1)
Category 
New 6 460 (72.8) 2 054 (62.5) 302 (58.8)
Retreatment 2 410 (27.2) 1 234 (37.6) 212 (41.2)
Disease 
classification 
Pulmonary 7 454 (84.0) 2 715 (82.6) 395 (76.8)
Extrapulmonary 1 211 (13.7) 497 (15.1) 94 (18.3)
Both 205 (2.3) 76 (2.3) 25 (4.9)
Smear diagnostic 
result
Positive 4 232 (47.7) 1 481 (45.0) 176 (34.2)
Negative 3 847 (43.4) 1 264 (38.4) 255 (49.6)
No smear 791 (8.9) 543 (16.6) 83 (16.1)
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Our study also showed that more retreatment patients were co-infec-
ted than new patients. This is similar to another SA study, in which 
97% of retreatment patients were tested for HIV and 78% were 
co-infected.[26] A study from India found that retreatment patients 
were less likely to be co-infected, but this was in a low HIV prevalence 
setting.[27]
In the Metro East GSA, smear microscopy should not be the only 
means of diagnosing TB, as 53.2% of HIV-positive patients and 
31.3% of HIV-negative patients had smear-negative, culture-positive 
TB. Culture is the gold standard for the diagnosis of TB, but it takes 
up to 6 weeks and is expensive, so sputum smear microscopy is the 
cornerstone of the diagnosis in many resource-limited settings. [28,29] 
Many studies have shown that smear microscopy has low sensitivity. [4,30] 
Recently GeneXpert, a nucleic acid test that produces results within 
2 hours, has been used in the majority of clinics in SA, and this should 
alleviate the problem of waiting for cultures.[31]
Sputum smear microscopy is useful to monitor the progress of 
TB disease.[27] According to the SA TB guidelines,[28] sputum smear 
microscopy should be done before treatment is initiated, at the end 
of the intensive phase (at 2 or 3 months) and at the end of treatment, 
particularly in patients who had positive bacteriological findings 
before treatment. At the end of the 3 months 11.6% of patients with 
smear-positive TB had not had a smear done, showing that clinics in 
the Metro East GSA were not following the guidelines. It is possible 
that these smears were not done because patients were not able to 
provide a sputum specimen.
Only 70.0% of TB patients had a successful outcome in the 
Metro East GSA, far below the target of 85%. This low percentage 
of successful outcomes may explain why the Western Cape has the 
highest TB notification rate in the country.[32] The WHO estimates 
that a treatment completion rate of 85% and a 70% case detection rate 
are required to have an impact on the TB epidemic in high-burden 
countries.[5] In 2013, the treatment success rate was 86% globally. In 
the same year, the success rate in SA was 77%.[5]
The Khayelitsha subdistrict had the highest proportion of 
unsuccessful treatment outcomes. This could be due to the high 
burden imposed by TB and HIV co-infection on the healthcare 
system. Khayelitsha is also one of the poorest areas of Cape Town, 
with high unemployment and more than 50% of dwellings being 
informal.[14,18]
HIV co-infection was associated with an unfavourable treatment 
outcome. This could be due to the negative impact of HIV on TB, 
increasing the risk of TB-related morbidity and mortality.[7] A study 
from Toronto[33] showed a high treatment failure rate (36%) in 
co-infected patients, and that HIV was an independent risk factor for 
not completing TB treatment. Another study, from Nigeria, found a 
treatment failure rate of 27% in HIV co-infected patients compared 
with 19% in HIV-negative patients.[34]
Unfavourable outcomes in co-infected patients may be due to a 
delay in diagnosis because of atypical clinical presentation, and it 
is also known that co-infected patients tend to have paucibacillary 
TB or low microbacterial colony counts.[35] This reduction in 
microbacterial count makes the diagnosis of TB by smear microscopy 
more difficult.
In contrast to other studies,[36] the present study showed no 
difference in treatment outcome between the sexes.
Patients who had had TB previously (retreatment cases) were 
significantly more likely to have an unfavourable TB treatment 
outcome than new patients. A number of studies have shown that 
retreatment patients are at an increased risk of having an unfavourable 
treatment outcome.[37] Retreatment was more common in co-infected 
patients, providing an added risk.[38] Furthermore, retreatment 
patients were more prone to drug-resistant TB and loss to follow-up, 
increasing the likelihood of an unfavourable outcome.[2,37]
Absence of sputum smear microscopy at diagnosis was also 
a significant risk factor for an unfavourable treatment outcome. 
Sputum smear microscopy may not be requested if there is an atypical 
clinical presentation of TB, such as absence of a cough and inability to 
produce sputum. Absence of sputum smear microscopy at diagnosis 
may also be due to health system-related failures. Most clinics do not 
have a physiotherapist to assist patients who are finding it difficult 
to produce sputum, sputum may not be requested owing to lack of 
resources or tardiness on the part of clinical staff, or the results may 
not be received by the clinic, or be received but not entered in the 
patient’s record.
Study strengths and limitations
The major strength of this study was the large database from an 
area with a high incidence of TB and a varying prevalence of HIV, 
showing the impact of HIV together with other factors. HIV status 
was confirmed from clinical records rather than self-reported, and 
the accuracy of the data was therefore likely to be good. Only 2.8% 
of patients were excluded because they did not have an HIV test 
result.
A major limitation was missing or incomplete data, and this may 
have affected the power of the study. It was a secondary analysis of 
data already collected, and the principal investigator (SM) was not 
Table 4. TB case notification case rate, proportion of TB patients co-infected with HIV based on the 2011 census,[12] and HIV 
prevalence by district from the 2012 antenatal survey[13] 
Subdistrict
Khayelitsha Eastern Northern Tygerberg
TB notification case rate 4 683/279 212
(1 677/100 000)
2 941/372 344
(790/100 000)
1 892/281 691
(672/100 000)
3 156/441 688
(715/100 000)
Proportion of TB patients with HIV 
co-infection
3 043/4 683
(65.0%)
1 347/2 941
(45.8%)
1 017/1 892
(53.8%)
990/3 156
(31.4%)
HIV prevalence (2012 antenatal survey) 37.1% 17.9% 26.2% 9.4%
Table 5. Comparison of diagnostic sputum smear results and 
sputum culture results at pretreatment in HIV-positive and 
HIV-negative patients
Sputum result
Culture result
 Total Positive, n (%) Negative, n (%) 
HIV-positive
Positive 1 216 (47.1) 110 (11.2) 1 326
Negative 1 364 (52.9) 869 (88.8) 2 233
Total 2 580 (100) 979 (100) 3 559
HIV-negative
Positive 1 674 (68.1) 75 (20.2) 1 749
Negative 783 (31.9) 295 (79.7) 1 078
Total 2 457 (100) 370 (100) 2 827
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able to trace missing information from the primary clinical records. 
In addition, there may have been recording and data-capturing errors 
that the principal investigator was not able to correct. Moreover, 
limited information was collected on patients on ETR.Net and 
we could therefore not adjust for known confounders such as 
socioeconomic status, education level and marital status. All patients 
with an unrecorded treatment outcome were regarded as having an 
unfavourable treatment outcome. Patients with unrecorded HIV 
status were excluded, and it is not known whether this group would 
have been more or less likely to be co-infected.
Conclusions
The incidence of TB is extremely high in the Metro East GSA of 
Cape Town, but the prevalence of co-infection with HIV varies 
across the subdistricts. Co-infection, retreatment and smear 
microscopy not done before treatment were factors significantly 
associated with an unfavourable treatment outcome. The Eastern 
and Northern subdistricts were significantly more likely to have 
favourable treatment outcomes compared with Khayelitsha, where 
both TB incidence and HIV co-infection were highest. More 
research is required to identify other risk factors for unfavourable 
treatment outcomes.
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